NXT2B

Navinci Diagnostics AB is a Swedish company specializing in biomolecular analysis for cancer and prenatal diagnostics. Based in Uppsala, it develops proprietary technology aimed at detecting and quantifying proteins, their interactions, and modifications in various biological samples, including tissue, cells, and blood. The company offers a range of products, including universal kits suitable for cultured cells and fresh-frozen or FFPE samples, as well as target-specific kits that are pre-optimized for specific variables. In addition to its product offerings, Navinci Diagnostics provides in-house immunostaining and custom assay services, enhancing its capabilities in the field of diagnostics.

Vivolux AB is a pharmaceutical company based in Mölndal, Sweden, focusing on drug discovery and development for cancer treatment. Founded in 2006, the company specializes in creating innovative therapies, including VLX600, an iron chelator that disrupts mitochondrial respiration to induce tumor cell death, and VLX1570, which inhibits the proteasome to promote apoptosis in cancer cells. Vivolux employs advanced culture systems for drug screening and lead optimization, enhancing the research capabilities of medical scientists. Their expertise lies in mechanistic studies of anticancer drugs, integrating a deep understanding of molecular interactions at the cellular level to develop effective treatments.